N-terminal Myristoylation Enhanced the Antimicrobial Activity of Antimicrobial Peptide PMAP-36PW

• Published in: Frontiers in cellular and infection microbiology Vol. 10; p. 450
• Main Authors: Liu, Yongqing, Li, Shengnan, Shen, Tengfei, Chen, Liangliang, Zhou, Jiangfei, Shi, Shuaibing, Wang, Yang, Zhao, Zhanqin, Liao, Chengshui, Wang, Chen
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 27-08-2020
• Subjects: anti-biofilm; antibacterial activity; antibacterial peptide Myr-36PW; antibacterial peptide PMAP-36PW; Cellular and Infection Microbiology; myristoylation; stability; antibacterial activity; antibacterial peptide PMAP-36PW; myristoylation; antibacterial peptide Myr-36PW; therapeutic efficacy; anti-biofilm; mechanism; stability
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2020.00450

Drug-resistant bacteria infections and drug residues have been increasing and causing antibiotic resistance and public health threats worldwide. Antimicrobial peptides (AMPs) are novel antimicrobial drugs with the potential to solve these problems. Here, a peptide based on our previously studied peptide PMAP-36PW was designed via N-terminal myristoylation and referred to as Myr-36PW. The fatty acid modification provided the as-prepared peptide with good stability and higher antimicrobial activity compared with PMAP-36PW
. Moreover, Myr-36PW exhibited effective anti-biofilm activity against Gram-negative bacteria and may kill bacteria by improving the permeability of their membranes. In addition, the designed peptide Myr-36PW could inhibit the bacterial growth of
ATCC 25923 and
GIM 1.551 to target organs, decrease the inflammatory damage, show an impressive therapeutic effect on mouse pneumonia and peritonitis experiments, and promote abscess reduction and wound healing in infected mice. These results reveal that Myr-36PW is a promising antimicrobial agent against bacterial infections.